Sanofi Acquires China Rights to Arrowhead’s Plozasiran for $395 Million
Sanofi has acquired the rights to develop and commercialize plozasiran, an investigational RNA interference (RNAi) therapeutic from Arrowhead Pharmaceuticals, in Greater China1234.
The deal was effected with Arrowhead's majority-owned subsidiary, Visirna Therapeutics124.
Plozasiran is designed to reduce apolipoprotein C-III (APOC3) and is being developed for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG)123.
Visirna will receive an upfront payment of $130 million from Sanofi, with up to $265 million in milestone payments tied to regulatory approvals for multiple indications in China13.
Arrowhead will also be eligible for royalties on net sales in Greater China as part of the license agreement1.
Sources:
1. https://www.thepharmaletter.com/pharmaceutical/arrowhead-unit-sells-china-rights-on-plozasiran-to-sanofi
2. https://arrowheadpharma.com/news-press/arrowhead-subsidiary-visirna-sells-rights-to-hypertriglyceridemia-candidate-plozasiran-in-greater-china-to-sanofi/
3. https://pharmaphorum.com/news/sanofi-grabs-chinese-rights-arrowhead-rare-disease-drug